{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:18:33Z","timestamp":1783498713567,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2025C02079"],"award-info":[{"award-number":["2025C02079"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ebiom.2026.106341","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:32:59Z","timestamp":1782232379000},"page":"106341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The three-dimensional perspective of CAR-T cell therapy in autoimmune diseases"],"prefix":"10.1016","volume":"129","author":[{"given":"Jiayi","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106341_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2026.106341_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib3","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib5","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200479","article-title":"Anti-CD19 CAR T-cell therapy in advanced stiff-person syndrome and concomitant myasthenia gravis","volume":"12","author":"Ayzenberg","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2026.106341_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2026.106341_bib7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2026.106341_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ebiom.2026.106341_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2026.106341_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101039","article-title":"Anti-CD19 CAR T cell therapy for refractory SLE-ITP","volume":"7","author":"Li","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-025-02554-1","article-title":"Anti-CD19 CAR-T cell therapy for acquired hemophilia a","volume":"39","author":"Schultze-Florey","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2026.106341_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/d41573-025-00085-z","article-title":"The race to reset autoimmune diseases","volume":"24","author":"Bhandari","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2026.106341_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/annrheumdis-2024-eular.1478","article-title":"Op0027 long-term safety and efficacy of car-t cell treatment in severe and treatment refractory autoimmune disease","volume":"83","author":"Taubmann","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ebiom.2026.106341_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2026.106341_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.ebiom.2026.106341_bib17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.ebiom.2026.106341_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19-CD38hiCD138+ subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2026.106341_bib19","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106341_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell\u2013mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2026.106341_bib21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial","volume":"32","author":"Fedak","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib22","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41423-022-00933-7","article-title":"Epigenetic regulation of B cells and its role in autoimmune pathogenesis","volume":"19","author":"Xiao","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ebiom.2026.106341_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ebiom.2026.106341_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib26","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106341_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: european research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2026.106341_bib28","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2026.106341_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy","volume":"12","author":"Ferla","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2026.106341_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2024.104261","article-title":"Minimal residual disease in multiple myeloma","volume":"54","author":"Moukalled","year":"2025","journal-title":"Presse M\u00e9d"},{"key":"10.1016\/j.ebiom.2026.106341_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ebiom.2026.106341_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101075","article-title":"CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome","volume":"7","author":"Korte","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"Chang","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2026.106341_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1900\/RDS.2005.2.121","article-title":"B cells in autoimmune diabetes","volume":"2","author":"Wong","year":"2005","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.ebiom.2026.106341_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100776","article-title":"Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis","volume":"6","author":"Hegelmaier","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib36","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ebiom.2026.106341_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2026.106341_bib38","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ebiom.2026.106341_bib40","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ebiom.2026.106341_bib41","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106341_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8+ T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4+ T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2026.106341_bib43","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2016.12.007","article-title":"Adoptive transfer of mRNA-transfected T cells redirected against diabetogenic CD8 T cells can prevent diabetes","volume":"25","author":"Fishman","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2026.106341_bib44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106341_bib45","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1182\/blood-2023-186669","article-title":"CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus - safety and preliminary efficacy data from a phase I clinical study","volume":"142","author":"Feng","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2026.106341_bib46","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.3390\/ijms26136051","article-title":"Targets for CAR therapy in multiple myeloma","volume":"26","author":"Bezborodova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2026.106341_bib47","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106341_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2026.106341_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ebiom.2026.106341_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies - evidence, safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ebiom.2026.106341_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/ANNALS-25-04559","article-title":"The U.S. food and drug administration's perspective on chimeric antigen receptor T-cell therapies for autoimmune and rheumatic conditions","volume":"179","author":"Tariq","year":"2026","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: Expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ebiom.2026.106341_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ebiom.2026.106341_bib54","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106341_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","article-title":"Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"15","author":"Einarsdottir","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ebiom.2026.106341_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ebiom.2026.106341_bib57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2026.106341_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106341_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ebiom.2026.106341_bib60","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106341_bib61","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405085121","article-title":"Dual ON\/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs","volume":"121","author":"Giordano Attianese","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2026.106341_bib62","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106341_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2026.106341_bib64","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106341_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2026.106341_bib66","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2026.106341_bib67","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ni0508-477","article-title":"Natural killer cell recognition of missing self","volume":"9","author":"K\u00e4rre","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2026.106341_bib68","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers12030706","article-title":"You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy","volume":"12","author":"Pfefferle","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ebiom.2026.106341_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ebiom.2026.106341_bib70","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2026.106341_bib71","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.ebiom.2026.106341_bib72","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:11:33Z","timestamp":1783498293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":72,"alternative-id":["S2352396426002240"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106341","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The three-dimensional perspective of CAR-T cell therapy in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106341"}}